The fact that there’s such a wall made me sad.
The fact that this wall is so long made me sick.
The fact that l had to find my boy’s name among 6,000 children left me crushed.
A child dying from cancer is wrong.
No mother has to find her child’s picture on such a wall.

Another year of sponsoring young investigators from kidney cancer community to attend 2026 AACR. May this experience broaden their perspectives, deepen their learning, and inspire them to pursue meaningful careers in cancer research!

Thank you @DrRanaMcKay for a day focusing on patients: updates on research & clinical trials, dietary advice, survivors stories…

youtube.com/watch?v=A2kh64…

SENATE: PASS THE MIKAELA NAYLON GIVE KIDS A CHANCE ACT!
@SenSchumer
@LeaderJohnThune
@SenSanders
@PattyMurray
@SenatorBaldwin
@timkaine
@ChrisMurphyCT
@SenatorAndyKim
@SenLBR

RNA binding by TFE3 fusion partners facilitates biomolecular condensate formation, which enhances RNAPII activity to drive pro-oncogenic transcriptional programs. PSPC1 is identified as a key co-condensate component. Can we dissolute TFE3 onco-
fusion condensates?

Please pass the Mikaela Naylon Give Kids a Chance Act without delay.@SenSanders
@SenMurray
@Hickenlooper
@ChrisMurphyCT
@SenatorHassan
@Sen_Alsobrooks
@SenLBR
@SenatorAndyKim
@SenatorBaldwin
@SenMarkey
@timkaine81458

Despite distinct genetic and transcriptional programs, tRCC and ccRCC share a VCAM1⁺ proximal tubule origin. Some tRCCs, however, may arise from other kidney lineages - plasticity that could explain its varied histology and presence of TFE3 fusions in ASPS and PEComa.

Our Florida team is the best! The 11th annual Joey’s Wings 5k was a success!

Excited to finally share our latest study on #TranslocationRCC #PEComas @NatureComms!
We generated the first ever, murine transgenic kidney tumor models of SFPQ-TFE3 - the most common MiT/TFE gene fusion implicated in both, tRCC and PEComas (Perivascular Epitheloid neoplasms). le for this fusion in regulating #mTORC1-driven lineage plasticity, with transcriptional downregulation of critical nephric lineage transcription factors like PAX8, that perfectly recapitulate human renal PEComas.
Additionally, we nominate the lysosomal V-ATPase complex as a central regulator of mTORC1 activity in tRCC, and a target-rich environment for therapeutic intervention in this deadly disease.
Grateful to all the co-authors, collaborators, reviewers, editors and funding sources who made this study possible! @adriannaamendes @LotanLab @eddieimada @MasayaBaba2 @terry_watnickmd @WMarstonLinehan @PeterArgani @yasserged @rmelias2 @nirmishsingla @allaf_mo @Joeyswings @KidneyCancer @kidneycan @CDMRP
nature.com/articles/s4146…

7 meetings in a day. Rallying for KCRP under CDMRP. We refuse to go backward!

The Malouf Lab at IGBMC (Strasbourg, France) is recruiting a postdoctoral researcher to join a translational research program focused on rare and treatment-resistant kidney cancers.

🔗 Full details here: igbmc.fr/en/job-offers/…
Let’s build something meaningful @SPBassociation

Life can be incredibly cruel. 14, what a beautiful age. Austen from Missouri was diagnosed with TFE3 rearranged PEComa overlapping with tRCC only 5 months ago. She passed away this morning. This hurts like hell.

Much respect to @srviswanathan recipient of Kidney Cancer Innovation/Discovery Grants! Rare subtype like tRCC often received less funding and attention. It takes dedication, creativity, and compassion to tackle diseases that are poorly understood and harder to treat. #KCRS25

🗣️Kidney Cancer Oral Abstracts #ASCO25

👉Abs4521: Dr #JAmesGeller presenting Nivo/Axitinib vs Nivo in pts with translocation RCC #AREN1721

🩺Clinical implications:
- Nivo/Axitinib (n=6) showed early efficacy ORR 33% and mPFS 10mo
- #TranslocationRCC remains a disease of unmet 📖Integrative clinical and molecular characterization of translocation renal cell carcinoma @ZiadBakouny @srviswanathan
🔗shorturl.at/aopSM

📖A genetic basis for sex differences in Xp11 translocation renal cell carcinoma @m_achom
🔗shorturl.at/3Vfbu
--------------------------------------------------------
n = 13
Median Age 16 (7-42)
9/13 under 18yo, 9/13 male

💉 Nivo + Axitinib (n=6) ORR 33% mPFS 10.5mo
💉 Nivo alone (n=5) ORR 0%. mPFS 1.8mo
💉 Axitinib alone (n=2) ORR 0%

👥@DrChoueiri @montypal @AlbigesL @TiansterZhang @DrRanaMcKay @tompowles1 @brian_rini @BraunMDPhD @DrKarieRuncie @PBarataMD @PavlosMsaouel @yekeduz_emre @DrYukselUrun @ReneeSaliby @drenriquegrande @bavilima @DRBakaloudiMD @ReginaBarCar @crisbergerot @kidneycan @KidneyCancer @ASCO @oncoalert @OncBrothers

Delighted to host @KidneyCancer model workshop @KCPUTSW

Press release on our recent TFE3 fusion condensate paper.
hopkinsmedicine.org/news/newsroom/…

Another peek into the transformative Kidney Cancer Patient Summit — where stories, science and support came together.

Thank you to @Joeyswings for the videography and support: bit.ly/420i4QS.

Our latest study in @EmboMolMed reveals how TFE3 fusions drive oxidative metabolism and ferroptosis resistance in translocation renal cell carcinoma (tRCC). We define tRCC as a novel metabolic subtype of renal cancer. @IGBMC @unistra @srviswanathan
🔗embopress.org/doi/full/10.10…

Please help us spread the words! Head over to trccproject.org to register to join us for an informative 1-hour session on Count Me In’s newest patient-partnered research initiative of the Broad Institute: the Translocation Renal Cell Carcinoma (tRCC) Project.